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Summary
Mutation scanning and direct DNA sequencing of all 50
exons of ABCR were completed for 150 families seg-
regating recessive Stargardt disease (STGD1). ABCR
variations were identified in 173 (57%) disease chro-
mosomes, the majority of which represent missense
amino acid substitutions. These ABCR variants were not
found in 220 unaffected control individuals (440 chro-
mosomes) but do cosegregate with the disease in these
families with STGD1, and many occur in conserved
functional domains. Missense amino acid substitutions
located in the amino terminal one-third of the protein
appear to be associated with earlier onset of the disease
andmay represent misfolding alleles. The twomost com-
mon mutant alleles, G1961E and A1038V, each iden-
tified in 16 of 173 disease chromosomes, composed
18.5% of mutations identified. G1961E has been as-
sociated previously, at a statistically significant level in
the heterozygous state, with age-related macular degen-
eration (AMD). Clinical evaluation of these 150 families
with STGD1 revealed a high frequency of AMD in first-
and second-degree relatives. These findings support the
hypothesis that compound heterozygous ABCR muta-
tions are responsible for STGD1 and that some hetero-
zygous ABCR mutations may enhance susceptibility to
AMD.
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Introduction
Stargardt disease (STGD; MIM 248200; McKusick
1998) is arguably the most common hereditary recessive
macular dystrophy and is characterized by juvenile to
young-adult onset, evanescent to rapid central visual im-
pairment, progressive bilateral atrophy of the foveal ret-
inal pigment epithelium (RPE) and neuroepithelium, and
the frequent appearance of yellow-orange flecks distrib-
uted around the macula and/or the midretinal periphery
(Stargardt 1909; Anderson et al. 1995). A clinically sim-
ilar retinal disorder, fundus flavimaculatus (FFM), often
manifests later onset and slower progression (Frances-
chetti 1963; Hadden and Gass 1976; Noble and Carr
1979). Despite historical nosologic separation (e.g.,
MIM 230100; McKusick 1992), results of linkage anal-
ysis suggested that STGD and FFM were most likely
allelic autosomal recessive disorders with slightly differ-
ent clinical manifestations, caused by mutations of a
single gene located within an ∼2-cM interval between
markers D1S406 and D1S236, at chromosome 1p13-
p21 (Kaplan et al. 1993; Anderson et al. 1995; Gerber
et al. 1995; Hoyng et al. 1996; Weber et al. 1996).
By a positional candidate approach, the causal gene
for recessive STGD (STGD1; MIM 248200) was iden-
tified as a photoreceptor-specific ATP-binding cassette
(ABC) transporter gene (ABCR; GenBank U88667; Ge-
nome Database 370748; MIM 601691); mutations seg-
regated appropriately with disease status, in both con-
sanguineous (homozygous) and outbred (compound
heterozygous) families with STGD1 (Allikmets et al.
1997b; Gerber et al. 1998; Nasonkin et al. 1998; Rozet
et al. 1998). Families with STGD1 showed a high fre-
quency of missense mutations in theABCR gene. In each
family with two identified mutant alleles, at least one
allele was a missense change or an in-frame deletion,
suggesting that most patients with STGD1 may have at
least one allele that retains partial function (Allikmets
et al. 1997b). Subsequently, a recessive “atypical” phe-
notype of progressive pigmentary retinopathy with cho-
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roidal atrophy, in a Spanish consanguineous family, was
shown, by linkage analysis, to colocalize in the same
chromosomal region at 1p13-p21 (Martinez-Mir et al.
1997). Direct sequencing demonstrated a 1-bp deletion
in exon 13 of ABCR that generated a frameshift early
in the coding region and a premature stop codon (Mar-
tinez-Mir et al. 1998). Individuals homozygous for this
null mutation were predicted to have no functional
ABCR protein, thus leading to a phenotype more severe
than that of STGD. Similarly, homozygosity for a splice-
site mutation in intron 30 (IVS301GrT)was identified
in another consanguineous family and was associated
with a severe phenotype of pigmentary retinopathy.
Compound heterozygous subjects with a 5′ splice-site
mutation in intron 40 (IVS405GrA) manifested a
milder, combined cone and rod dystrophy (Cremers et
al. 1998).
Age-related macular degeneration (AMD [ARMD2;
MIM 153800]) shares several phenotypic similarities
with STGD, including the accumulation of material in
and under the RPE (drusen), loss of photoreceptor func-
tion, a progressive geographic atrophy of the macular
RPE, and occasional disciform macular degeneration
(Klein et al. 1978). In a screen for alterations in ABCR
in a cadre of 167 individuals with isolated AMD, both
deletions and putative amino acid substitutions were
identified in one allele of ABCR in one-sixth (16%) of
the sample set (Allikmets et al. 1997a; Dean et al. 1998)
but not in a large control group, strongly suggesting a
disease association.
The protein product of ABCR is expressed only in the
retina—specifically, in the rod photoreceptors—and is
absent from cone photoreceptors and RPE cells (Allik-
mets et al. 1997b; Sun and Nathans 1997). Western
blotting and immunohistochemistry of macaque, bovine,
and mouse retinas showed that ABCR encodes rim pro-
tein in the rims and incisures of the discs of the rod outer
segments, supporting important roles forABCR in either
phototransduction or disc structural morphology (Aza-
rian and Travis 1997; Illing et al. 1997; Sun andNathans
1997). Therefore, different structural alterations in this
protein may predispose different phenotypic dystrophic
processes, such as no functional protein causing a severe
progressive pigmentary retinopathy, compound hetero-
zygotes developing STGD1, or some single-copy mutant
alleles predisposing to a late-onset phenotype of AMD.
Interfamilial and intrafamilial variability of clinical
phenotype in classic STGD1, manifested either in age at
onset or severity of retinal disease, may be influenced by
the pairings of mutant alleles.We report here the analysis
of ABCR mutations in a series of 150 families with
STGD1.
Subjects and Methods
Family Studies
Of 278 families with STGD/FFM, most of which were
of northern or central European ancestry and were as-
certained during 1985–98, 150 families were informa-
tive for the design and objectives of this study. Pedigrees
of 46 of these families were published previously (fig. 1
in the article by Anderson et al. [1995]) and those of
the other 104 are shown in figures1 and 4. Three fam-
ilies, in two of which the parents were first cousins, orig-
inated in Saudi Arabia but were from different tribes.
All families were ascertained through theMedical Retina
and Ocular Genetics Service of the Cullen Eye Institute,
Baylor College of Medicine, Houston (by R.A.L.), and
by regional, national, and international referral from
ophthalmologists, geneticists, and support groups. For
each kindred, a detailed family history and pedigreewere
obtained through personal interviews with appropriate
family members. For individuals outside the Houston
area, available ophthalmologic, photographic, fluores-
cein angiographic, electrophysiologic, and psychophys-
ical records were retrieved. The anamnestic and oph-
thalmologic information for each individual was scored
as either affected or normal, by a single observer (R.A.L.)
who had no prior knowledge of linkage or mutation
data on any family. Each subject or, on behalf of minors
or wards, the responsible adult signed a consent for par-
ticipation in these investigations that was approved by
the Baylor Affiliates Review Board for Human Subject
Research (Anderson et al. 1995).
The essential and defining features of STGD were (1)
pedigrees with at least one living affected individual
compatible with autosomal recessive inheritance; (2) an
ophthalmoscopically characteristic retinal disorder in
families with both parents living; (3) bilateral central
visual loss with both “beaten metal” elliptical foveal
dystrophy and temporal pallor of the optic discs, doc-
umented by retinal color photography, with or without
yellow-pigment epithelial flecks in the macular and/or
retinal “near periphery”; and (4) the characteristic fluo-
rescein angiographic feature of a dark choroid (Bla-
charski 1988). The other criteria for characterization of
the clinical and angiographic diagnosis of STGD, ascer-
tainment of the families, and methods used for their
collection, including for the consanguineous families
from Saudi Arabia, are described elsewhere (Anderson
et al. 1995; Allikmets et al. 1997b). For comparison,
220 racially matched individuals with no personal his-
tory or known family history of STGD served as controls
(Anderson et al. 1995; Allikmets et al. 1997b).
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Figure 1 Pedigrees of families segregating STGD. Squares indicate males, circles indicate females, and diamonds indicate sex unknown;
a single digit below a symbol indicates the number of individuals. Blackened symbols represent individuals affected with STGD. An asterisk
(*) to the upper left of a symbol indicates an individual affected with AMD. A number sign (#) to the upper left of a symbol indicates an
individual affected with retinitis pigmentosa. A diagonal line indicates a decedent. A double horizontal line between a mating pair indicates
consanguinity. The family number is given above each pedigree. Specific individuals in a given family are identified by a hyphen and a two-
digit number below the symbol. The pedigrees expand the cadre of families reported by Anderson et al. 1995. Eleven families (AR19, AR31,
AR59, AR80, AR125, AR129, AR205, AR215, AR218, AR271, and AR324) reported in figure 1 of the article by Anderson et al. [1995] have
a family history of AMD.
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Figure 2 Age at onset of visual impairment in families with
STGD. The Y-axis indicates the number of families from the cohort
of the 150 families studied for ABCR mutations; the X-axis indicates
the age at onset, in half-decade increments. The majority of families
(119 [∼80%] of 150) manifest visual impairment within the first 2
decades of life.
Molecular Methods
ABCR alterations were detected by a strategy of com-
bined SSCP and heteroduplex analyses under optimized
conditions, as described elsewhere (Roa et al. 1993; Al-
likmets et al. 1997b). Sequencing was performed on an
ABI sequencer, with both dye-primer and dye-terminator
chemistry (Allikmets et al. 1997b). DNA sequencingwas
performed on each strand, for all exons inwhich variants
were identified by mutation-screening methods.
Results
Clinical Resources
Of the 150 families analyzed by molecular methods
(figs.1and 4; fig. 1 in Anderson et al. 1995), 78 had one
affected individual, 68 included two or more affected
siblings, and 6 (AR33, AR279, AR331, AR341, AR375,
and AR418) had two generations unequivocally af-
fected with STGD\FFM, without historic evidence for
consanguinity. One family, AR289, had a family history
of retinitis pigmentosa (MIM 601718). Of those af-
fected, 116 (51%) were males, and 113 (49%) were
females. With few exceptions, a concordance in age at
onset was noted among affected siblings, regardless of
sex, with a tendency toward an earlier age at diagnosis
(by 1–2 years) for the second (and subsequent) affected
siblings, as would be expected with enhanced parental
and physician suspicion after the disorder had been di-
agnosed in the elder affected sibling. Although initial
enrollment emphasized families with classic ages at on-
set, of 5–19 years (Anderson et al. 1995), other families
with later onset of visual symptoms shared identical
spectra of progressive loss of visual acuity, ophthalmo-
scopic abnormalities of the ocular fundus, and angio-
graphic characteristics, including both a dark choroid
and the evolution of infiltrative and sequentially atrophic
pigment epithelial flecks.
One approach to assess the clinical severity of a pair
of mutant alleles was to determine the age at onset of
visual impairment, from anamnestic medical records and
interviews with selected familymembers. Among the 278
families with STGD, 406 affected individuals had a
mean age at first reported visual loss of years.15.8 9.6
Of the 150 families with STGD for which the ABCR
mutation analyses were performed, the mean age at on-
set was years. We segregated the mean age15.2 8.8
at reported onset of visual loss by 5-year intervals, be-
ginning at age 5 years (fig. 2). Only two families (AR398
and AR613) reported onset at age 4 years; for simplicity,
they were grouped into the youngest half-decade of on-
set, 5–9 years. Among the several families with affected
cousins, the nuclear family identified and enrolled first
was scored first. As was expected from the emphasis in
our initial recruitment (Anderson et al. 1995), 58 (39%)
families experienced onset at ages 5–9 years, 40 (27%)
at ages 10–14 years, and 21 (14%) at ages 15–19 years.
However, 21% of the families in this series had onset at
ages 20 years.
Ophthalmoscopic features of the disease, including se-
verity of macular atrophy, extent and density of macular
and peripheral flecks, rapidity or severity of involution
and atrophy of flecks, and presence of metaplasia of
peripheral RPE, could not be readily correlated to age
at onset. This correlation was difficult because individ-
uals and families were recruited from throughout North
America and from Saudi Arabia and because the req-
uisite photographic and fluorescein angiographic records
were not rigorously sequential for individual patients or
necessarily contemporaneous with age at onset or at di-
agnosis. In general, however, the earlier the onset, the
more rapid was the loss of central acuity, the more ex-
tensive were the areas of atrophy of the foveal RPE, and
the more extensive and atrophic were the flecks in the
midretinal RPE, depending on the age of the affected
individual at the time of retinal photography ( Hadden
and Gass 1976; Noble and Carr 1979; Armstrong et al.
1998). Similarly, the distribution of the flecks and the
extent of atrophy tended to parallel the duration of the
disease since onset of symptoms, rather than the age at
onset itself.
Four families, AR55, AR290, AR363, and AR534,
included two nuclear families related as cousins, with
different ages at onset. These families were useful for
the analysis of the effect of a single shared mutant allele
when paired with a second and different allele, in two
limbs of the same kindred. For example, AR55 included
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Table 1
ABCR Mutations in Stargardt Disease
Exon
Nucleotide
Change
Amino
Acid
Change No. Exon
Nucleotide
Change
Amino
Acid
Change No. Exon
Nucleotide
Change
Amino
Acid
Change No.
2 0071GrA R24H 1 19 2894ArG N965S 3 36 51961GrA Splice 2
3 0161GrA C54Y 1 21 3113CrT A1038V 16 51962TrC Splice 1
0179CrT A60V 1 22 3211insGT FS 1 37 5281del9 PAL1761del 1
0203CrG P68R 1 3212CrT S1071L 1 38 5459GrC R1820P 1
0223TrG C75G 1 3215TrC V1072A 1 39 5512CrT H1838Y 1
6 0634CrT R212C 1 3259GrA E1087K 1 5527CrT R1843W 1
0664del13 FS 1 3322CrT R1108C 6 40 55851GrA Splice 1
0746ArG D249G 1 23 3364GrA E1122K 1 5657GrA G1886E 1
8 1007CrG S336C 1 3385GrT R1129C 1 5693GrA R1898H 4
1018TrG Y340D 1 3386GrT R1129L 2 57145GrA Splice 8
11 1411GrA E471K 1 24 3602TrG L1201R 1 42 5882GrA G1961E 16
12 1569TrG D523E 1 25 3610GrA D1204N 1 58981GrT Splice 3
1622TrC L541P 1 28 4139CrT P1380L 4 43 5908CrT L1970F 1
1715GrA R572Q 2 4216CrT H1406Y 1 5929GrA G1977S 1
1715GrC R572P 1 4222TrC W1408R 4 60051GrT Splice 1
13 1804CrT R602W 1 4232insTATG FS 1 44 6079CrT L2027F 11
1822TrA F608I 2 42535GrT Splice 1 6088CrT R2030X 1
1917CrA Y639X 1 29 4297GrA V1433I 1 6089GrA R2030Q 1
1933GrA D645N 1 4316GrA G1439D 2 6112CrT R2038W 1
14 2005delAT FS 1 4319TrC F1440S 1 45 6148GrC V2050L 2
2090GrA W697X 1 4346GrA W1449X 1 6166ArT K2056X 1
21601GrC Splice 1 30a 4462TrC C1488R 2 6229CrT R2077W 1
16 2453GrA G818E 1 4457CrT P1486L 1 46 6286GrA E2096K 1
2461TrA W821R 1 30b 4469GrA C1490Y 3 6316CrT R2106C 1
2536GrC D846H 1 45391GrT Splice 1 47 6391GrA E2131K 1
2552GrC G851D 1 31 4577CrT T1526M 7 6415CrT R2139W 1
17 2588GrC G863A 11 4594GrA D1532N 3 6445CrT R2149X 1
19 2791GrA V931M 2 35 4947delC FS 1 48 6543del36 1181del12 1
2827CrT R943W 1 36 5041del15 VVAIC1681del 2 6709insG FS 1
2884delC FS 1 5087GrA S1696N 1
NOTE.—FS  frameshift.
two (of three) affected siblings (AR55-03 and AR55-07)
who had onset of visual loss by age 8 years and whose
affected first cousin, once removed (AR55-11), had onset
at age 16 years. In AR290, the affected siblings (AR290-
06 and AR290-07) each had onset of visual impairment
at age 16 years, and their cousin (AR290-10) was af-
fected during her late teens. In family AR534, the pro-
band (AR534-05) experienced impaired vision at age 10
years, and his three first cousins (AR534-10, AR534-11,
and AR534-12) had onset of symptoms at ages 8–10
years.
In addition to our observation that single-copy mu-
tations in ABCR were found in ∼16% of 167 unrelated
and isolated patients with AMD, the self-reported fre-
quency of any form of AMD among parents (age 155
years) and grandparents in 145 of these 150 families
was assessed by a telephone or mail poll. Positive re-
sponses were evaluated further by recovery and review
of clinical records, retinal photographs, and available
fluorescein angiograms. Of these 145 families, 31 (21%)
reported a positive family history of AMD in the lineage
of direct descent to the affected sibship(s). Since most
individuals with early aging features in the retina (dru-
sen) are subjectively asymptomatic, this self-reported
“prevalence” can be viewed as an underestimate of true
ophthalmoscopic prodromal variants, both because oph-
thalmoscopy often is not performed on asymptomatic
individuals and because those with minor findings often
are not informed of pathologic abnormalities that do
not affect vision.
Molecular Analysis
Heteroduplex and SSCP analyses were used to screen
the 50 exons (Allikmets et al. 1998; Azarian et al. 1998;
Cremers et al. 1998) of ABCR for alterations in the
affected proband from each of the 150 families segre-
gating STGD. In 17 exons (table 1), no disease-associ-
ated alterations were identified. All 50 exons were
screened for variants in 220 unrelated, unaffected con-
trol individuals. Any alterations identified in the STGD
proband and not identified in the 220 control individuals
were evaluated for segregation within the familiy. In the
150 families with STGD studied, 183 ABCR variations
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were identified and considered to be pathologic changes
that likely were disease causing (table 1). In families
AR33 and AR534, three distinct disease chromosomes
were identified; therefore, a total of 302 disease chro-
mosomes were screened. Family AR33 showed a pseu-
dodominant inheritance pattern in which an affected fa-
ther married an unrelated female carrier; in family
AR534, affected first cousins shared a single disease
chromosome.
These disease-associated alterations either change the
predicted ABCR amino acid sequence or likely affect
ABCR mRNA splicing. They cosegregate with the dis-
ease in the pedigrees and were not found in440 control
chromosomes. The common 2588GrC mutation iden-
tified in 11 of the 302 disease chromosomes was also
found in 2 of 440 control chromosomes; 2453GrA was
identified in 1 disease chromosome and in 1 of 440 con-
trol chromosomes (Allikmets et al. 1997a; Dean et al.
1998). The 183 STGD1-associated ABCR mutations
consist of 89 different nucleotide changes, including 80
mutations that, by conceptual translation, affect ABCR
protein structure, 64 that cause missense amino acid sub-
stitutions, 6 that result in nonsense codons, 7 that cause
frameshift mutations, and 3 that cause in-frame dele-
tions (table 1). There also were 9 different predicted
splice-site mutations. Thirty-four (43%) of the 79 single-
nucleotide changes occurred at CpG dinucleotides
presumably mediated by deamination of 5-methylcyto-
sine (Coulondre et al. 1978). Of these, 29 are transition
mutations, and 5 are transversion mutations.
Two or more mutations were identified in 59 of the
150 families studied. In 10 (7%) families (AR31,AR106,
AR128, AR189, AR215, AR254, AR264, AR265,
AR285, and AR305), two mutations occurred on a sin-
gle chromosome, resulting in several complex alleles. In
4 (AR31, AR106, AR128, and AR189) of these 10, a
mutation was identified on the second disease chro-
mosome. For the double-mutant chromosomes in the
compound heterozygous families (AR31: Y340D and
R572Q; AR106: E471K and E2131K; AR128: R572Q
and G863A; and AR189: L541P and A1038V) and in
those families in which the second disease chromosome
was not identified (AR215: H1406Y and V2050L;
AR264: D1204N and L2027F; AR254: D249G and
R1898H; AR265: G863A and R1898H; AR285:
27145GrA and 2884delC; and AR305: G863A and
R1898H), in three cases (AR128, AR265, and AR305)
each mutation on the double-mutant chromosome had
been identified independently as disease causing in other,
unrelated families with STGD1 (table 1). In five families
(AR31, AR189, AR215, AR254, and AR264) with dou-
ble-mutant chromosomes, one of themutations had been
identified in other, unrelated families with STGD1. In
one family (AR285), a common splice-site mutation was
paired on the same chromosome with a frameshift allele.
In the remaining family (AR106) with a double-mutant
chromosome, neither ABCR alteration was identified in
other families with STGD1 or in controls, but the dou-
ble-mutant chromosome segregated with the disease.
Thus, mutations were identified on both chromosomes
in 53 (35%) of the 150 families studied. Three (AR293,
KKESH71, and KKESH214) of these 53 families were
identical by descent for polymorphic markers flank-
ing the ABCR mutations and had the same mutation
(VVAIC1681del, G1439D, and V931M, respectively)
segregating on each disease chromosome. The remaining
50 families were compound heterozygotes for ABCR
mutations.
In 59 families, only one mutation was found by these
mutation-screening methods. Thus, mutations were
identified on a single disease chromosome, including six
double-mutant chromosomes, in 65 (43%) of the 150
families studied. In total, mutations were found in 118
(79%) of the 150 families and in 173 (57%) of the 302
disease chromosomes. Seven mutant alleles, including
six missense amino acid substitutions and one splice-
site mutation (G863A, A1038V, R1108C, T1526M,
G1961E, L2027F, and 57145GrA) accounted for
41% of the disease-causing mutations identified in this
cohort. In three instances, identical codons were affected
by different base-pair substitutions, yielding different
predictedmissense amino acid substitutions (R572Qand
R572P; R1129C and R1129L) or amissense substitution
and a stop codon (R2030Q and R2030X). Intriguingly,
in each case, these mutations represent a change of a
CpG dinucleotide in either the CGA or the CGC codon
for the basic amino acid arginine.
Twenty-two of the 64 missense amino acid substitu-
tions occurred in predicted conserved domains of the
ABCR protein (fig. 3). Predicted conserved domains in-
clude 790 amino acid positions, whereas 1,483 amino
acids occur in regions not conserved, when compared
with other ABC transporters. Therefore, missense mu-
tations inABCR occur with equal frequency in predicted
conserved regions (22 [2.8%] of 790) as in regions not
conserved (42 [2.8%] of 1,483).
Age-at-Onset Correlations with ABCR Mutations
In family AR33, the father and the paternal aunt of
four patients affected with STGD are also affected with
STGD, suggesting a dominant or pseudodominant in-
heritance pattern (fig. 4). Mutation analysis of ABCR
and segregation analysis in this family revealed two mu-
tations in each affected individual, which is consistent
with recessive inheritance. Interestingly, in family AR33,
siblings with identical ABCR compound heterozygous
mutations are concordant for the half-decade of onset
of visual symptoms (fig. 4). These observations suggest
that the selected combination of specific ABCR mutant
Lewis et al.: ABCR in Stargardt Disease 429
Figure 3 ABCR missense mutations in conserved domains. Missense mutations are shown on a two-dimensional schema of the ABCR
protein. Protein domains were determined by the dense alignment surface transmembrane-prediction program (Cserzo et al. 1997) and by
homology to other ABC transporters. Transmembrane domains are shown as diagonally hatched boxes: transmembrane region 1 begins at
codon 648 and ends at codon 855; transmembrane region 2 begins at codon 1674 and ends at codon 1898. ATP-binding domains are shown
as checkered boxes: domain 1 begins with the Walker A motif at codon 965 and ends with the Walker B motif at codon 1093; domain 2 begins
with the Walker A motif at codon 1975 and ends with the Walker B motif at codon 2102. The gray-shaded vertical area represents a conserved
hydrophobic domain, the significance of which is not known (Savary et al. 1997). Missense mutations are shown above the diagram, for
mutations outside these functional domains, and below the diagram, for mutations within these domains. Twenty-two mutations were identified
in the 790 amino acid residues comprising the predicted conserved domains of the ABCR protein, whereas 42 mutations were identified in
1,483 amino acid residues outside these domains. These data demonstrate that missense mutations are distributed evenly across the ABCR
protein.
alleles is an important determinant for the age at onset
of the disease.
To investigate the hypothesis that the position of mu-
tations in the ABCR protein may be important in de-
termination of age at onset, mutation position (X-axis)
was graphed and compared with age at onset (Y-axis)
for the 53 families in which both disease alleles were
identified (fig. 5). Individuals AR33-01, AR33-11,
AR534-05, and AR534-10 are shown independently be-
cause they have different genotypes. Specific ages at on-
set were assigned according to the earliest onset in a
sibship. Pedigrees assigned the same ages at onset were
ordered further according to the next earliest onset for
a sibling in the family. Families with only one affected
individual were placed lower on the Y-axis (fig. 5).
Mutations 5′ to nucleotide 2588 (codon 863) are rare
among individuals with onset at age 114 years (fig. 5).
Importantly, putative null mutations, including frame-
shift and early nonsense mutations, were observed more
frequently in compound heterozygous alleles from pa-
tients with onset at age !10 years (5 of 46 vs. 3 of 60;
fig. 5). Frameshift mutations in early-onset patients are
predicted by conceptual translation to encode an ABCR
protein lacking the second transporter domain and,
therefore, are likely to be null alleles. Frameshift mu-
tations in later-onset patients are predicted to truncate
only the carboxy-terminal tail of ABCR and might retain
some transporter function.
To investigate further the relationship between mu-
tation and age at onset, allelic series were constructed
for unrelated families that share one specific ABCRmu-
tant allele (allele 1 in table 2). Five series were con-
structed for mutations present in five or more compound
heterozygous families (table 2). Different families with
the same combination of alleles (e.g., AR326 and
AR391, both with genotype L2027F/T1526M; AR376
and AR393, both with genotype A1038V/R1108C)
usually have similar ages at onset, as was shown for
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Figure 4 Pedigree AR33, a family with STGD that manifests a
pseudodominant inheritance pattern. Symbols are defined as in the
legend tofigure 1. The individual represented by the checkered circle
had the presence of drusen identified on ophthalmologic examination
and subsequently developed disciform macular degeneration. ABCR
genotypes are given below the symbols. For the compound hetero-
zygous individuals, the age at onset, in years, is given below the ge-
notype. WT  wild type.
the pseudodominant pedigree (AR33) discussed above.
However, variation in self-reported age at onset, even by
11 decade, was noted for two families with identical
ABCR compound heterozygous genotypes (age 8 years
for family AR417 and age 20 years for family AR274,
each with genotype G1961E/A1038V), suggesting either
modifier alleles or environmental factors affecting dis-
ease expression or different sensitivity to reported age
at onset.
One pedigree, AR534, includes two nuclear families
related as cousins, with similar ages at onset; both sets
of compound heterozygous ABCR alleles were identi-
fied. Individual AR534-05, with genotype P1380L/
W821R, presented with visual impairment at age 10
years, whereas his cousins, each with genotype P1380L/
E1122K, had onset of visual impairment at ages 8–10
years. Two compound heterozygous families, AR335
and AR341, had both mutations in the same exon
(F608I/D645N in exon 13 and P1380L/W1408R in
exon 28, respectively) and had an early age at onset of
6 years.
Discussion
At least five distinct disease phenotypes (retinitis pig-
mentosa, cone-rod dystrophy, Stargardt macular dystro-
phy, FFM, and AMD) have been associated with ABCR
mutations. Alterations in the ABCR gene likely are re-
sponsible for a substantial amount of retinal pathology.
Further information about the clinical manifestations of
ABCR mutations is essential to the understanding of
retinal disease. We have expanded our molecular anal-
ysis of ABCR by investigating 150 families with STGD
for DNA-sequence alterations in the 50 coding exons.
The mutation-screening methods used in this study will
not detect large DNA rearrangements or variations in
noncoding regions, and the analysis did not include the
promoter or regulatory regions. Despite these limita-
tions, we identified a substantial percentage (57%) of
mutant chromosomes. Many single-nucleotide changes
occur at a known mutation hot spot, a CpG dinucleo-
tide, but they occur at a frequency in ABCR that is
similar to that observed in other human genes (Cooper
and Krawczak 1993). Sixty-four of the 80 nucleotide
changes that should affect ABCR protein structure cause
missense amino acid substitutions. These missense ami-
no acid substitutions occur with equal frequency in pre-
dicted conserved regions and those regions not con-
served, compared with other human ABC transporter
proteins (Allikmets et al. 1995, 1996; Dean and Allik-
mets 1995). These data emphasize the importance of
screening the entire coding sequence of ABCR to search
for mutant alleles, not merely to search for that portion
predicted to encode conserved domains. Ten families
have two ABCR variants that were found on the same
disease chromosome and that were not identified in 220
control individuals, emphasizing the importance of seg-
regation analysis of all ABCR variants identified in fam-
ilies with STGD1. The origin and possible mechanism
for double-mutant chromosomes or complex alleles are
unknown. However, this phenomenon also has been ob-
served at the cystic fibrosis locus, CFTR (Zielenski and
Tsui 1995). The effect on phenotypic expression of a
second mutant allele in a single disease chromosome
remains to be determined for a large cadre of such
families.
From the 53 families in which both disease chromo-
somes containing ABCR mutations were identified, we
have gleaned phenotype/genotype correlations from clin-
ical information on each family. The collective findings
suggest that missense mutations in the ABCR gene re-
gion encoding the amino terminal one-third of the pro-
tein are associated with an earlier age at onset (fig. 5).
Likewise, frameshift mutations that occur more 5′ in the
ABCR gene usually are associated with an earlier age at
onset. Late age-at-onset of the disease is associated with
the absence of mutations 5′ to codon 863 (nucleotide
2588). In general, identical ABCR genotypes manifest
similar ages at onset, for symptomatic disease, as ex-
emplified by a pseudodominant family (AR33) with dif-
ferent members having two distinct genotypes (fig. 4).
Considerable variation in the age at onset of visual
symptoms in STGD has been noted by many authors.
Klein and Krill (1967) reported the range of age at onset,
among 27 cases, to be 7–65 years. Hadden and Gass
(1976), after excluding anyone of age 160 years, to avoid
confusion with AMD, identified a mean age at onset,
among 28 patients, of 17 years but a range of 6–45 years.
Of 67 patients studied by Noble and Carr (1979), 47
Figure 5 Age at onset of visual impairment in those families with STGD1 in which both ABCR mutant alleles were identified. At the
bottom of the figure, the primary sequence of the ABCR protein, with conserved functional domains, is shown: the amino terminus is to the
left, and the carboxy terminus is to the right. The different combinations of mutant alleles are shown above the ABCR protein sequence: M 
missense mutation, F  frameshift, Del  deletion, Stp  nonsense-codon mutation, and S  splice-site mutation. In each horizontal row, both
mutant alleles are shown for each family with a compound heterozygous ABCR mutation. The three families that are homozygous for mutant
alleles have a slash between the mutations. The family pedigree number is given to the right (all are “AR” pedigrees, unless otherwise specified),
with the age at onset, in years. Horizontal dashed lines indicate half-decades for age at onset.
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Table 2
ABCR Allelic Series
MUTATION(S)
PEDIGREE
AGE AT
ONSET
(YEARS)
MEAN AGE
AT ONSET
 SD
(YEARS)Allele 1 Allele 2
G863A Y340D, R772Q AR31 8 19.6  12.7
51961GrA AR307 10
A1038V AR290 16
57145GrA AR314 25
58981GrT AR336 39
A1038V R572P AR321 6 12.5  6.9
S1071L AR358 6
L1970F AR428 6
51962TrC AR71 7
G1961E AR417 8
L2027F AR181 9
R1898H AR78 14
G863A AR290 16
G1961E AR274 20
R1108C AR393 20
R1108C AR376 25
P1380L W1408R AR341 6 8.2  1.5
E1122K AR534 8
2005delAT AR357 8
D1532N AR423 9
W821R AR534 10
G1961E A1038V AR417 8 14.3  4.5
C75G AR427 12
C1490Y AR370 13
21601GrC AR218 14
42535GrT AR373 19
A1038V AR274 20
L2027F R602W AR88 9 13.0  5.5
A1038V AR181 9
R2149X AR263 9
T1526M AR326 19
T1526M AR391 19
(70%) had onset in the first 2 decades of life, but 11
(16%) had onset in the 3d decade and 6 (9%) in the
4th decade. Among 49 patients, Gelisken and DeLaey
(1985) noted onset of visual symptoms at age !15 years
in 32 (65%) patients and at age 126 years in 4 (8%)
patients. The 41 patients described by Blacharski (1988)
had a mean age at onset of 22.5 years but an age range
of 5–64 years.
Among the 150 families for which results of mutation
analysis are reported here, the mean age at onset of visual
symptoms was years. Approximately 80%15.2 8.8
of families had onset at age !20 years, and 16% had
onset in the 3d decade of life and 5% in the 4th decade.
Of our total cohort of 278 families with STGD, 10 had
onset of symptoms in the 5th decade of life and 3 in the
6th decade. Thus, the distribution in age at onset of
visual loss spreads over 5 decades and is wider than that
traditionally reported. The observation that combina-
tions of milder ABCR alleles are associated with later
ages at onset may suggest overlap with the age range
for the diagnosis of AMD. It also is conceivable that a
single mutant ABCR allele that is dysfunctional over
many decades would have phenotypic consequences.
From this perspective, the association of self-reported
family history of AMD in 21% of our cohort of families
with STGD1 is higher than expected. This association
raises the potential of increased risk of AMD among
family members with STGD1 who carry one mutant
ABCR allele. However, the prevalence of AMD in the
population is quite high, that is, 110% of individuals of
age 165 years (Klein et al. 1992). Therefore, a stringent
clinical ascertainment of a large cohort of relatives with
STGD1, combined with rigorous epidemiologic inves-
tigation and statistical analysis, must establish the sig-
nificance of AMD individuals heterozygous for ABCR
mutations, among family members with STGD1.
Nevertheless, we already have identified a statistically
significant incidence of heterozygous ABCR variants in
two different AMD cohorts (Allikmets et al. 1997b;
Dean et al. 1998). We reported previously that three
AMD-associated ABCR variants (R1898H, G1961E,
and 6519D11bp) (Allikmets et al. 1997a) had been iden-
tified in families with STGD1 (Allikmets et al. 1997b).
Interestingly, four other STGD1-causing ABCR muta-
tions (E471K, R1129L, 51961GrA, and L1970F) in
these new families were documented previously as
AMD-associated ABCR variants (Allikmets et al.
1997a). Importantly, the G1961E allele, identified as one
of the two most frequent variants in both the Utah and
the Boston cohorts of AMD patients (Allikmets et al.
1997a), was also the most frequently identified ABCR
mutant allele in our cohort of 150 families with STGD1.
In 6 of the 16 families with STGD1 who had a G1961E
disease chromosome, the other mutant allele also was
identified; in all 16 cases, G1961E cosegregated with the
disease. Thus, G1961E is a pathologic mutation and not
a benign variant.
In the absence of a functional assay for ABCR, it is
difficult to establish a role in pathogenicity for any in-
dividualABCR variant, particularlymissense amino acid
substitutions. However, the absence of the variants in a
large control population, their confirmed cosegregation
with the disease, and their occurrence in conserved func-
tional domains for many of the mutant alleles indicate
that these variants cause disease and are not benign.
Some missense mutations occur in regions of ABCR not
yet assigned functional significance. The fact that these
mutations were not found in controls and that they co-
segregated with STGD1 suggests that they also are path-
ologic alterations.
The most completely characterized ABC transporter
gene is CFTR. In a summary of over 550 variants, Zie-
lenski and Tsui (1995) demonstrated that the mutations
are distributed over the entire gene and are not clustered
in the ATP-binding domains or the transmembrane
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regions. As with ABCR, the number of complex CFTR
alleles described shows the importance of scanning the
entire gene. Many CFTR mutants are associated with
altered processing of the protein, resulting in retention
of CFTR in the Golgi apparatus and/or endoplasmic
reticulum. Intriguingly, those ABCRmissense mutations
reported here that are located more toward the amino
terminus appear to be associated with earlier onset of
the disease. These observations are consistent with the
possibility that such mutations represent severe-misfold-
ing alleles or that they result in altered processing of the
protein. Functional analysis of such mutant alleles is
required, to elucidate the consequences of eachmutation
on protein structure, processing, and function.
In summary, we firmly established a role for ABCR
in classic STGD1 and further supported the hypothesis
that heterozygous ABCR alleles represent a dominant
susceptibility locus for AMD. Future in vitro functional
studies and animal models with selected ABCR mutant
alleles will delineate the pathophysiologic steps from an
ABCRmutation to the phenotype of a retinal dystrophy.
Such studies likely will amplify the prominent role of
this gene in retinal pathology and will determine its role
in normal retinal physiology.
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